Burkins v. Corizon Resident Agent

CourtDistrict Court, D. Maryland
DecidedJanuary 20, 2022
Docket1:21-cv-00244
StatusUnknown

This text of Burkins v. Corizon Resident Agent (Burkins v. Corizon Resident Agent) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Burkins v. Corizon Resident Agent, (D. Md. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

WILLIAM BURKINS,

Plaintiff,

v. Civil Action No.: SAG-21-244

CORIZON RESIDENT AGENT, et al.,

Defendants.

MEMORANDUM OPINION Self-represented Plaintiff William Burkins filed this civil rights action against Corizon Health Inc., RN Uzoamaka Nwabuwa, NP Clarice Aryiku, Dr. Robert P. Williams, and Mable Fletcher on January 28, 2021. ECF No. 1. Burkins filed an Amended Complaint, pursuant to the Court’s direction, on March 2, 2021. ECF No. 4. Defendants filed a Motion to Dismiss or, Alternatively, for Summary Judgment on June 29, 2021, and a Supplement to the Motion on December 28, 2021. ECF Nos. 24, 29. In support of their dispositive motion, Defendants have provided the affidavits of Robert Williams, M.D. (ECF No. 24-4), Uzoamaka Nwabuwa, RN (ECF No. 24-9), Clarice Aryiku, NP (ECF No. 24-10), Mable Fletcher (ECF No. 24-11), and Gedion Atnafu, M.D. (ECF No. 29-1), along with Burkins’s relevant medical records (ECF Nos. 24-5 – 24-8). Burkins filed a response and Defendants replied. ECF No. 28.1 A hearing is not necessary. See Local Rule 105.6 (D. Md. 2021). For the reasons explained below, the Court will grant Defendants’ Motion.

1 Burkins filed a response to Defendants’ Motion on October 13, 2021. ECF No. 27. However, his arguments concern his diagnosis with the COVID-19 virus rather than the claims outlined in the instant complaint regarding a shoulder injury and his Hepatitis C treatment. See id. On October 25, 2021, Defendants filed a reply indicating that Burkins’s response is instead a response related to another of his cases pending in this District, Civil Action No. LKG-21-629. ECF No. 28. It appears Burkins mistakenly filed his response in the incorrect case. Defendants have attached the correct response that Burkins submitted in Civil Action No. LKG-21-629, which, in light of Burkins’s self-represented status, the Court will consider as Burkins’s opposition to Defendants’ Motion. See ECF No. 28-1. Background I. Hepatitis C Treatment In his Complaint as amended, Burkins asserts that he informed staff at Jessup Correctional Institution (“JCI”) that he had a Hepatitis C infection (“HCV”) upon his incarceration in September 2018. ECF No. 4-1 at 2. Inmates with HCV are enrolled in the chronic care clinic, where Burkins

asserts treatment should have started immediately, but had still not been completed two and a half years later. Id. According to Burkins, he reported to medical on December 3, 2020, for a chronic care appointment with Dr. Robert Williams to follow up with his Hepatitis C treatment. Id. at 1. “HCV is an infection caused by a virus that attacks the liver and leads to inflammation;” chronic infections, caused by HCV, damage the liver resulting in fibrosis and cirrhosis. Atnafu Decl., ECF No. 29-1 at ¶ 5. Dr. Gedion Atnafu, a physician who serves on the Infectious Diseases Panel, explains that inmates with chronic HCV infections are enrolled in the chronic care clinic for clinical evaluation and laboratory testing to determine liver function. Id. at ¶ 8. A chronic care provider refers inmates with HCV to the Infection Disease Panel (“the Panel”), which reviews

cases and discusses options for direct-acting antiviral (“DAA”) medications used to treat HCV. Id. The Panel recommends further evaluation or DAA treatment. Id. Burkins was seen for a chronic care visit on April 24, 2019, at which time Dr. Mofikapara Wright recommended a “Hep C work up,” and ordered genotype and viral load testing. Medical Records, ECF No. 24-5 at 91-93. It was noted during a sick call that a fibroscan, which measures the degree of fibrosis or scarring on the liver, should be considered if Burkins had a detectable viral count. Medical Records, ECF No. 24-6 at 5; ECF No. 29-1 at ¶ 6. A fibroscan was ordered on May 20, 2019, by NP Motunrayo Adegorusi, who noted that labs had been completed and Burkins had consented to treatment. ECF No. 24-6 at 21. The fibroscan was completed on May 24, 2019, showing fibrosis at F0-F1 levels, meaning Burkins had either no liver scarring or mild liver scarring. Id. at 34-35. On August 27, 2019, Burkins saw NP Aryiku and informed her that he had not received any follow up treatment after his fibroscan in May. Id. at 49. NP Aryiku requested a consult with the Panel. Id. at 53. A determination regarding Burkins’s HCV treatment had not been made when

he inquired again during a sick call on September 20, 2019. Id. at 51. Pursuant to the Panel’s direction, on October 12, 2019, a Hepatitis B vaccine and a PT/INR test, to monitor Burkins’s liver function, were ordered. Id. at 66; see ECF No. 29-1 at ¶ 6. At a sick call on October 21, 2019, Burkins requested HCV treatment and was referred to his chronic care provider. ECF No. 24-6 at 71-72. Burkins received Hepatitis B vaccination shots on October 29 and November 29, 2019. Id. at 74-75. Burkins was seen in chronic care by NP Adegorusi on December 16, 2019, at which time the Panel still had not made any further determinations regarding Burkins’s HCV treatment. Id. at 81. Burkins denied any difficulties with his bowel or bladder and NP Adegorusi noted that his

viral load and liver function were to be monitored after treatment was completed. Id. On January 4, 2020, NP Adegorusi ordered laboratory testing requested by the Panel. Id. at 87-88. In light of Burkins’s low viral count, on January 27, 2020, the Panel recommended that a viral load test be repeated in three months and then the case would be reviewed again. Id. at 94. Dr. Atnafu noted that Burkins’s viral load had decreased from 15,000 to 3,090 and had a Fibroscore of F0-F1. Id. at 95; ECF No. 29-1 at ¶ 19. NP Adegorusi ordered laboratory testing and a Hepatitis A vaccination on the Panel’s recommendation. ECF No. 24-6 at 96; ECF No. 24-7 at 1. Dr. Atnafu attests that the Panel recommended monitoring Burkins’s condition because his decreased viral load indicated that his HCV may resolve without treatment. ECF No. 29-1 at ¶ 19. On February 8, 2020, Burkins received a Hepatitis A vaccine. ECF No. 24-7 at 6-7. Thereafter, due to the COVID-19 pandemic HCV treatment reviews by the Panel were suspended between April and August 2020. ECF No. 29-1 at ¶ 21. During that time, Burkins’s viral load increased to 10,500. ECF No. 24-7 at 27. Burkins visited NP Aryiku on June 10, 2020, and it was noted that HCV RNA testing would be ordered following completion of his vaccinations. Id. at

14. On July 11, 2020, NP Adegorusi saw Burkins in chronic care and ordered a consult from the Panel. Id. at 17. Burkins received another Hepatitis A vaccination on July 28, 2020. Id. at 24. Burkins’s laboratory results indicated that his PT/INR results were within normal limits on July 15, 2020, and his viral load was 12,600 on June 10, 2020. ECF No. 24-8 at 72, 74. On August 15, 2020, during a follow up appointment, NP Adegorusi noted that she contacted the Panel to follow up on Burkins’s treatment plan. ECF No. 24-7 at 32. Dr. Atnafu attests that he does not know why Burkins was not referred to the Panel for further consultation, but states that there was a backlog due to the COVID-19 pandemic. ECF No. 29-1 at ¶ 28. Burkins was not seen in chronic care again until December 3, 2020, where Dr. Robert

Williams noted that his viral load was 12,600 in June 2020 and his liver function tests from December 2019 “were essentially normal.” ECF No. 24-8 at 18. Burkins expressed his concern that he would not be able to complete treatment prior to his release date. Id. The Department of Public Safety and Correctional Services mandates that DAA treatment should not be started if an inmate is scheduled for release within six months of treatment to ensure that there is sufficient time to complete a DAA treatment course. ECF No. 29-1 at ¶ 29. Burkins was released from JCI on March 5, 2021. ECF No. 24-8 at 77. II.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gregg v. Georgia
428 U.S. 153 (Supreme Court, 1976)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Monell v. New York City Dept. of Social Servs.
436 U.S. 658 (Supreme Court, 1978)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Wilson v. Seiter
501 U.S. 294 (Supreme Court, 1991)
Hudson v. McMillian
503 U.S. 1 (Supreme Court, 1992)
Hope v. Pelzer
536 U.S. 730 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Scott v. Harris
550 U.S. 372 (Supreme Court, 2007)
Dulaney v. Packaging Corp. of America
673 F.3d 323 (Fourth Circuit, 2012)
Bizzie Walters v. Todd McMahen
684 F.3d 435 (Fourth Circuit, 2012)
Libertarian Party of Virginia v. Charles Judd
718 F.3d 308 (Fourth Circuit, 2013)
Iko v. Shreve
535 F.3d 225 (Fourth Circuit, 2008)
Farmer v. Brennan
511 U.S. 825 (Supreme Court, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
Burkins v. Corizon Resident Agent, Counsel Stack Legal Research, https://law.counselstack.com/opinion/burkins-v-corizon-resident-agent-mdd-2022.